Immunology
Advancing from CAR T-cell therapies to modified NK cell therapies
Chimeric antigen receptor (CAR) T-cell therapies have quickly become promising candidates for the treatment of many cancers. However, other immune cell types, such as natural killer (NK) cells, may be effective for some cancers, such as solid tumors, that are traditionally challenging for CAR T therapies. The science behind this concept is worth examining. Read More
Personalized cell therapies offer hope for some of the toughest cancers
Complete with a long-term vision of developing a pipeline of oncology therapies that modulate the functional immune system, Sotio of the Czech Republic is breaking into the world of autologous immuno-oncology therapies. The company's goal is to eventually become a prominent European pharmaceutical firm, according to Radek Špíšek, PhD, CEO and founding scientist of Sotio, who spoke with ScienceBoard.net in a recent interview. Read More
Collaboration targets new treatments for brain diseases
Developing more effective methods to deliver drugs across the blood-brain barrier is the goal of a new collaboration being led by the Wyss Institute for Biologically Inspired Engineering at Harvard University. Read More
NIH initiative tackles structural racism in biomedical research
A new framework to tackle structural racism was introduced by the U.S. National Institutes of Health (NIH) in a commentary published in the journal Cell on June 10. The initiative is an ambitious effort by the NIH to spur widespread, systematic changes across the biomedical research enterprise. Read More
Leveraging past flu pandemics helps build universal flu vaccine
Targeting regions of the influenza virus that do not often change may be an effective strategy for developing next-generation universal flu vaccines, according to new research published in Science Translational Medicine on June 2. Researchers interrogated immune responses from the 2009 H1N1 influenza pandemic to determine which targets to include in new vaccines. Read More
COVID-19 therapies could come from existing drugs
At least four drugs that have already been approved by the U.S. Food and Drug Administration may be effective as COVID-19 therapies, according to a study published on June 3 in Nature Communications by researchers from the Scripps Research Institute in La Jolla, CA. Read More
Single-cell study discovers how antibody regulators develop in tissue
The development process of immune cells important for establishing long-term immunity has been revealed through detailed single-cell techniques. A new study, published in the journal Science Immunology on May 28, examined extracted tonsils and lymph nodes to establish how human T follicular cells specialize in the body. Read More
Accenture report highlights growth in 'New Science'
Combining health and science technology to deliver more precise and effective treatments is driving growth in the life sciences market, according to a new market report produced by Accenture. The company calls the trend "New Science" and predicts it will lead to more personalized treatments for patients. Read More
The business of science: Taking your idea to the next level
If you are a scientist with an idea or a product that you think might be successful, then starting a company might be the career choice for you. In an interview with ScienceBoard.net, Olga Kubassova, PhD, CEO of Image Analysis Group, shares helpful information on launching a science startup. Read More
FDA updates requirements for COVID-19 vaccine EUAs
The U.S. Food and Drug Administration (FDA) issued a new guidance document on May 25 that updates previously issued guidance and sets expectations for future COVID-19 vaccine emergency use authorizations (EUAs) during the pandemic. Read More
Conferences
CPhI North America
August 10-12
Philadelphia, Pennsylvania United States
Bioprocessing Summit
August 16-19
Boston, Massachusetts United States
6th Annual CAR-TCR Summit
August 30 - September 2
Online
European Congress of Immunology (ECI) 2021
September 1-4
Belgrade Serbia
Medical Affairs Strategic Summit (MASS)
September 13-15
New Brunswick, New Jersey United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter